But, at the same time, for the third quarter, the company ... Mounjaro, Ozempic, Wegovy, and Zepbound will likely feature somewhat narrower margins after accounting for all of these expansion costs.

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...